ReviewEndocrine reviews2017
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.
Review in Endocrine reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Is radioiodine necessary for patients with low-risk differentiated thyroid cancer after thyroidectomy: a pooled analysis of ESTIMABL2 and IoN trials.Frontiers in oncology · 2025Pooled it
- Health-Related Quality of Life following Total Thyroidectomy and Lobectomy for Differentiated Thyroid Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2022Pooled it
- Thyroid carcinoma follow-up: tertiary to primary care transition in Portugal.Endocrine connections · 2026Article
- Evolving Practices in Low-Risk Papillary Thyroid Cancer: Impact of the 2015 ATA Guidelines.Current oncology (Toronto, Ont.) · 2026Article
- Nomogram for postoperative pathological stratification of ≥0.2 cm clinically significant lymph node metastasis burden in pN1 papillary thyroid carcinoma: development and validation using L2 ridge penalized logistic regression.Frontiers in endocrinology · 2026Article
- Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study.Frontiers in endocrinology · 2026Article
- Article
- Impact of the 2015 American Thyroid Association Guidelines on Treatment of Low-Risk Thyroid Cancer.Laryngoscope investigative otolaryngology · 2025Article
- Medullary Thyroid Carcinoma Detected by Routine Health Screening Had Better Clinical Outcome and Survival.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
- Dynamic Risk Stratification Integrated with ATA Risk System for Predicting Long-Term Outcome in Papillary Thyroid Cancer.Cancers · 2023Article
- Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.Journal of radiological protection : official journal of the Society for Radiological Protection · 2023Article
- Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis.The Journal of clinical endocrinology and metabolism · 2023Review
- Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- Systematic evaluation of the anti-tumor effect of Phellinus linteus polysaccharide in thyroid carcinoma in vitro.Molecular biology reports · 2022Article
- Thyroid lobectomy for low-risk thyroid cancers.Annals of the Royal College of Surgeons of England · 2022Article
- Relationship ofActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022Article
- Hemithyroidectomy versus total thyroidectomy in the intermediate-risk differentiated thyroid cancer: the Italian Societies of Endocrine Surgeons and Surgical Oncology Multicentric Study.Updates in surgery · 2021Article
- Post-Surgical Ablative or Adjuvant Radioiodine Therapy Has No Impact on Outcome in 1-4 cm Differentiated Thyroid Cancers without Extrathyroidal Extension.Journal of clinical medicine · 2021Article
- Association between preoperative serum TSH and tumor status in patients with papillary thyroid microcarcinoma.Endocrine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Controversy exists over optimal management of low-risk differentiated thyroid cancer. This controversy occurs in all aspects of management, including surgery, use of radioactive iodine for remnant ablation, thyroid hormone supplementation, and long-term surveillance. Limited and conflicting data, treatment paradigm shifts, and differences in physician perceptions contribute to the controversy. This lack of physician consensus results in wide variation in patient care, with some patients at risk for over- or undertreatment. To reduce patient harm and unnecessary worry, there is a need to design and implement studies to address current knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.